ID
16702
Beschrijving
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Relapse Report
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Trefwoorden
Versies (1)
- 01-08-16 01-08-16 -
Geüploaded op
1 augustus 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Beschrijving
New Lesion Specification
Beschrijving
Lesion number
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0221198
- UMLS CUI [1,2]
- C0750480
Beschrijving
Provide relevant code number for Method of Evaluation and Disease Site. lf "Other'' applies, use code 99 and specify.
Datatype
integer
Alias
- UMLS CUI [1]
- C2911685
Beschrijving
Method of Evalution
Datatype
text
Alias
- UMLS CUI [1]
- C2911685
Beschrijving
Site of Lesion
Datatype
integer
Alias
- UMLS CUI [1]
- C0449685
Beschrijving
Disease Site
Datatype
text
Alias
- UMLS CUI [1]
- C0449685
Beschrijving
Date of Evaluation
Datatype
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0221198
- UMLS CUI [1,3]
- C0031809
Similar models
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0750480 (UMLS CUI [1,2])
C0221198 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,3])